Novus Therapeutics (NVUS) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Novus Therapeutics (NASDAQ:NVUS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

According to Zacks, “Novus Therapeutics, Inc. is a pharmaceutical company. It focused on the acquisition, development and commercialization of ear, nose and throat products. The company’s platform consists of OP-01 Foam Platform and OP-02 Surfactant Program. Novus Therapeutics, Inc., formerly known as Tokai Pharmaceuticals Inc., is based in Irvine, United States. “

Separately, ValuEngine raised Novus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 25th.

NVUS opened at $3.70 on Friday. Novus Therapeutics has a fifty-two week low of $1.52 and a fifty-two week high of $8.61. The firm has a market cap of $34.38 million, a PE ratio of -1.61 and a beta of 3.57.

Several institutional investors and hedge funds have recently bought and sold shares of NVUS. National Asset Management Inc. lifted its holdings in shares of Novus Therapeutics by 345.9% during the third quarter. National Asset Management Inc. now owns 45,000 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 34,908 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Novus Therapeutics by 28.6% during the third quarter. Renaissance Technologies LLC now owns 251,556 shares of the biopharmaceutical company’s stock worth $1,175,000 after buying an additional 55,968 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Novus Therapeutics by 73.5% during the third quarter. Vanguard Group Inc. now owns 135,599 shares of the biopharmaceutical company’s stock worth $633,000 after buying an additional 57,450 shares in the last quarter. Finally, Vanguard Group Inc lifted its holdings in shares of Novus Therapeutics by 73.5% during the third quarter. Vanguard Group Inc now owns 135,599 shares of the biopharmaceutical company’s stock worth $633,000 after buying an additional 57,450 shares in the last quarter. 35.97% of the stock is owned by institutional investors.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).

Featured Story: Net Asset Value

Get a free copy of the Zacks research report on Novus Therapeutics (NVUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply